OS Therapies Incorporated (OSTX) Actualités

Form 8-K - Current report

OS Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update

Topline Data from Phase 2b clinical trial of OST-HER2 in Osteosarcoma expected to be released in December 2024 OS Therapies, Inc. (NYSE-A: OSTX...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB

OS Therapies to Present at The Spartan Capital Investor Conference

OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical...

Form 8-K - Current report

Join OS Therapies’ Exclusive Live Investor Webinar and Q&A Session on October 30

OS Therapies (NYSE American: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC...

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors

Concurrently, the Company accepted the resignations of Dr. Colin Goddard and Mr. Joacim Borg OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the...

OS Therapies to Present at the LD Micro Main Event XVII

OS Therapies (NYSE American: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate...

OS Therapies to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

OS Therapies (NYSE American: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate...

OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Completes Last Patient Visit

Company to ring Closing Bell at NYSE on Thursday, October 3, 2024 Interviews scheduled with Fintech.TV and Schwab Network OS Therapies (NYSE...

OS Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugate (tADC)-Based Therapeutic Candidates

First therapeutic candidate targets Breast Cancer, Lung Cancer and Gastric Cancer Second therapeutic candidate targets platinum-resistant...

OS Therapies to Present at H.C. Wainright 26th Annual Global Investment Conference

OS Therapies (NYSE American: OSTX) (“OS Therapies” or “the Company”), an ADC and Immunotherapy research and clinical-stage biopharmaceutical...